Matches in Wikidata for { <http://www.wikidata.org/entity/Q104288995> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- Q104288995 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 9ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104288995 description "article scientifique publié en 2020" @default.
- Q104288995 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104288995 description "scientific article published on 09 December 2020" @default.
- Q104288995 description "wetenschappelijk artikel" @default.
- Q104288995 description "наукова стаття, опублікована 9 грудня 2020" @default.
- Q104288995 name "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 name "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 name "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 type Item @default.
- Q104288995 label "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 label "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 label "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 prefLabel "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 prefLabel "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 prefLabel "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 P1433 Q104288995-38B1B990-CE9B-4922-ACD9-2D2A6B5E41B1 @default.
- Q104288995 P1476 Q104288995-DB9DCB66-5F00-46A5-B290-D955172FD93C @default.
- Q104288995 P2093 Q104288995-915F37F8-81DD-482B-8B15-1E618B70F3B0 @default.
- Q104288995 P2093 Q104288995-B6DED669-06C8-4B52-8814-7162B0877FAE @default.
- Q104288995 P31 Q104288995-1636790E-430D-4C4B-A261-8A1EA0CCD232 @default.
- Q104288995 P356 Q104288995-D7AAB37F-9905-46BB-92A3-D4E5C08D5E08 @default.
- Q104288995 P577 Q104288995-9452FDDF-30D6-4F69-A272-95B7960BE645 @default.
- Q104288995 P698 Q104288995-E2E2C5DF-6361-4790-8123-DE1487A35C0E @default.
- Q104288995 P921 Q104288995-3D27C25A-7580-4FAE-832E-18A71BF5BFCB @default.
- Q104288995 P356 J.JHEP.2020.09.016 @default.
- Q104288995 P698 33309114 @default.
- Q104288995 P1433 Q15724402 @default.
- Q104288995 P1476 "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis" @default.
- Q104288995 P2093 "Cumali Efe" @default.
- Q104288995 P2093 "Staffan Wahlin" @default.
- Q104288995 P31 Q13442814 @default.
- Q104288995 P356 "10.1016/J.JHEP.2020.09.016" @default.
- Q104288995 P577 "2020-12-09T00:00:00Z" @default.
- Q104288995 P698 "33309114" @default.
- Q104288995 P921 Q786844 @default.